Peer Review reports
From: Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
| Original Submission | ||
|---|---|---|
| 6 Apr 2022 | Submitted | Original manuscript |
| 25 Apr 2022 | Reviewed | Reviewer Report |
| 26 Apr 2022 | Reviewed | Reviewer Report |
| 14 Jul 2022 | Reviewed | Reviewer Report |
| 16 Aug 2022 | Author responded | Author comments - Carlos A. Torres-Duque |
| Resubmission - Version 2 | ||
| 16 Aug 2022 | Submitted | Manuscript version 2 |
| 12 Oct 2022 | Author responded | Author comments - Carlos A. Torres-Duque |
| Resubmission - Version 3 | ||
| 12 Oct 2022 | Submitted | Manuscript version 3 |
| 19 Oct 2022 | Author responded | Author comments - Carlos A. Torres-Duque |
| Resubmission - Version 4 | ||
| 19 Oct 2022 | Submitted | Manuscript version 4 |
| 26 Oct 2022 | Author responded | Author comments - Carlos A. Torres-Duque |
| Resubmission - Version 5 | ||
| 26 Oct 2022 | Submitted | Manuscript version 5 |
| 6 Nov 2022 | Author responded | Author comments - Carlos A. Torres-Duque |
| Resubmission - Version 6 | ||
| 6 Nov 2022 | Submitted | Manuscript version 6 |
| 10 Nov 2022 | Author responded | Author comments - Carlos A. Torres-Duque |
| Resubmission - Version 7 | ||
| 10 Nov 2022 | Submitted | Manuscript version 7 |
| Publishing | ||
| 16 Nov 2022 | Editorially accepted | |
| 28 Nov 2022 | Article published | 10.1186/s12890-022-02246-x |
You can find further information about peer review here.